Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Wow what bad news is next?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jun 14, 2022 7:56am
156 Views
Post# 34754330

RE:RE:RE:RE:RE:Wow what bad news is next?

RE:RE:RE:RE:RE:Wow what bad news is next?
StockingUp21 wrote:

Ignoring major parts of the whole story is what got you here

 

MrMugsy wrote:

 

woundedknee wrote: That's right. Markets are down due to high inflation and a sure recession in the near future. ATE has been trading solely on its cash position as management has failed its shareholders; the markets don't forget all the insider trades leading up to the crash of ATE's share price.  And Mugsy, I'll say this. You've got a pair to keep buying this stock, even if it is in dribs and drabs. It may pay off if you're young enough to see lt. Lets hope the new era of Antibe rewards your undying loyalty, even though I think it's futile. gl


Thanks Wounded ... hope all is good on your end !




Ignoring what?
Got you where?

Welcome to crazy markets - where you always have to be ready for a downturn.

If you lived through the mutual fund era and the dot-com bust and the financial crisis of 2008, you know exactly what to do right now.

You know value.  You know that cash is king !!!!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities